9 01, 2018 M. Rosaria Raspollini et.al, Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma Diatech Pharmacogenetics2018-01-15T11:18:58+01:00 Leggi di più
7 12, 2017 Chiara Pesenti et. al, MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay Diatech Pharmacogenetics2017-12-13T11:48:09+01:00 Leggi di più
21 11, 2017 Giovanna De Meglio et. al, A32 How can molecular heterogeneity impact on treatment choice in advanced colorectal cancer? Diatech Pharmacogenetics2018-01-30T10:42:42+01:00 Leggi di più
21 11, 2017 Roberta Minari et. al, Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy Diatech Pharmacogenetics2018-01-30T10:43:34+01:00 Leggi di più
6 11, 2017 Emanuela Romagnoli et. al, A25 Management of folinic acid administration in patients with metastatic colo-rectal cancer Diatech Pharmacogenetics2018-01-30T10:46:45+01:00 Leggi di più
6 11, 2017 Elena Ongaro et al., A24Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer patients: the ROAD study Diatech Pharmacogenetics2017-11-21T15:16:30+01:00 Leggi di più
18 09, 2017 Graziella Pinotti et al.,1335PEGFR T790M detection in TKI-naïve NSCLCs carrying sensitive EGFR mutations Diatech Pharmacogenetics2017-10-02T14:48:56+02:00 Leggi di più
18 09, 2017 Elena Ongaro et al., 552PMutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study Diatech Pharmacogenetics2020-01-22T09:23:08+01:00 Leggi di più
8 09, 2017 Rossella Bruno et al., Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. Oncology Letters Diatech Pharmacogenetics2017-09-12T10:02:30+02:00 Leggi di più
24 08, 2017 Annamaria Ruzzo et al., Dihydropyrimidine dehydrogenase pharmaco- genetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. British Journal of Cancer Diatech Pharmacogenetics2017-08-28T16:02:44+02:00 Leggi di più